QFQin Fu

Qin Fu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Qin Fu has a total of 73 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A Targeted LC-MS/MS Assay of a Health Surveillance Panel and Its Application to Chronic Kidney Disease

    by Qin Fu, Casey W. Courtelin Johnson, Lesley A. Inker, Jennifer E. Van Eyk, The CRIC Study Investigators

    Robust and reproducible assays capable of specific and quantitative monitoring of multiple biologically important proteins, among the thousands of human plasma proteins, can be used to represent the overall health of an individual and distinguish health versus disease. In this study, we established an LC-MS assay to monitor a Health Surveillance Panel (HSP), comprising 60 circulating plasma proteins selected based on their biological functions and/or disease associations. Plasma samples were prepared for proteomic analysis in an automated process and analyzed using an optimized, scheduled LC-MRM assay composed of 60 endogenous proteins monitored by 364 transitions from 117 proteotypic peptides, along with their stable isotopically labeled standard peptides. For each proteotypic peptide, a quantifier ion and at least two qualifier ions were selected based on consistent peak area ratios, a linear response for the quantifier ion, and a low limit of quantification. As proof of concept, we evaluated the performance of our HSP assay in a case–control study of progressive chronic kidney disease (CKD). Reduced plasma concentrations of alpha-2-antiplasmin, antithrombin-III, and immunoglobulin heavy constant alpha 1 correlated with CKD, with p-values <0.05. These results demonstrate that CKD-associated differences can be detected with a multiplexed HSP assay panel.

  • Quantifying the ∼75–95% of Peptides in DIA-MS Data Sets that Were Not Previously Quantified

    by Gautam Saxena, Qin Fu, Aleksandra Binek, Jennifer E Van Eyk

    We have developed a novel algorithm termed GoldenHaystack (GH) that was designed for enhanced peptide quantification of data-independent acquisition liquid-mass spectrometry (DIA-LC-MS) data files regardless of whether the amino acid sequences are subsequently assigned to the quantified peptide. The two central ideas behind GH are: (a) for sufficiently sized projects (e.g., ≥∼30 LC-MS files), pairs of peptides that coelute exactly in one subset of LC-MS files do not necessarily coelute exactly in a different subset of files, and (b) the ion intensity ratios between MS2 ions for any given peptide tend to stay the same across samples, but the ion intensity ratios of MS2 ions between different peptides tend to differ substantially across different samples. GH thus analyzes a project holistically: It uses multi-partite matching to match both MS2 (primarily) and MS1 (secondarily) ions across all samples, separates and regroups the MS ions into unique analyte quantifiable signatures (UAQS), reduces stochastic noise, and then quantifies those UAQS. In this paper, GH is compared to DIA-NN, a common algorithm used in DIA-MS proteomic analysis, and we demonstrate that GH (a) quantifies and identifies with better FDR accuracy known peptides found in FASTA search spaces (∼5-25% of analytes in DIA-MS data sets), (b) quantifies the remaining ∼75-95% of unassigned peptides that would be typically unquantified and unreported, and (c) runs ∼40-200× faster (or ∼1-10× faster than the LC-MS). Specifically, without a FASTA or spectral library, GH can deconvolute and accurately quantify chimeric LC-MS spectra. The use of a FASTA file occurs during an optional peptide identification step and is deployed only after the analytes in the MS files have already been quantified. We provide details of GH performance on several existing proteomics data sets, including plasma, cerebrospinal fluid, and cells.


  • Enhancing Proteomics Quality Control: Insights from the Visualization Tool QCeltis

    by Manasa Vegesna, Niveda Sundararaman, Ajay Bharadwaj, Kirstin Washington, Rakhi Pandey, Ali Haghani, Blandine Chazarin, Aleksandra Binek, Qin Fu, Susan Cheng, et al.

    Large-scale mass-spectrometry-based proteomics experiments are complex and prone to analytical variability, requiring rigorous quality checks across each step in the workflow: sample preparation, chromatography, mass spectrometry, and the bioinformatics stages. This includes quality control (QC) measures that address biological and technical variation. Most QC approaches involve detecting sample outliers and monitoring parameters related to sample preparation and mass spectrometer performance. Evaluating these parameters regularly is essential for reliable downstream analysis and proteomics research. Here, we introduce "QCeltis", a Python package designed to facilitate automated QC analysis across the proteomics workflow, aiding in the identification of technical biases and consistency verification. QCeltis is a versatile tool for detecting QC issues in large-scale data-independent acquisition proteomics experiments by not only identifying sample preparation and acquisition issues but also aiding in differentiating between QC issues vs batch effects. QCeltis is available for command-line use in Windows and Linux environments. We present three case studies showcasing QCeltis's capabilities across different data sets, including depleted plasma, whole blood vs plasma, and dried blood spot samples, emphasizing its potential impact on large-scale proteomics projects. This package can be used to enhance data reliability and enable nuanced downstream analysis and interpretation for proteomics studies.


  • A Proteomics Pipeline for Generating Clinical Grade Biomarker Candidates from Data‐Independent Acquisition Mass Spectrometry (DIA‐MS) Discovery

    by Qin Fu, Manasa Vegesna, Niveda Sundararaman, Eugen Damoc, Tabiwang N. Arrey, Anna Pashkova, Emebet Mengesha, Philip Debbas, Sandy Joung, Dalin Li, et al.

    Clinical biomarker development has been stymied by inaccurate protein quantification from mass spectrometry (MS) discovery data and a prolonged validation process. To mitigate these issues, we created the Targeted Extraction Assessment of Quantification (TEAQ) software package that uses data‐independent acquisition analysis from a discovery cohort to select precursors, peptides, and proteins that adhere to analytical criteria required for established targeted assays. TEAQ was applied to DIA‐MS data from plasma samples acquired on a new high resolution accurate mass (HRAM) mass spectrometry platform where precursors were evaluated for linearity, specificity, repeatability, reproducibility, and intra‐protein correlation based on 8‐ or 11‐point loading curves at three throughputs. This data can be used as a general resource for developing other targeted assays. TEAQ analysis of data from a case and control cohort for inflammatory bowel disease (n=492) identified 1110 signature peptides for 326 quantifiable proteins from the 1179 identified proteins. Applying TEAQ analysis to discovery data will streamline targeted assay development and the transition to validation and clinical studies.


  • A Proteomics Pipeline for Generating Clinical Grade Biomarker Candidates from Data‐Independent Acquisition Mass Spectrometry (DIA‐MS) Discovery

    by Qin Fu, Manasa Vegesna, Niveda Sundararaman, Eugen Damoc, Tabiwang N. Arrey, Anna Pashkova, Emebet Mengesha, Philip Debbas, Sandy Joung, Dalin Li, et al.

    Clinical biomarker development has been stymied by inaccurate protein quantification from mass spectrometry (MS) discovery data and a prolonged validation process. To mitigate these issues, we created the Targeted Extraction Assessment of Quantification (TEAQ) software package that uses data‐independent acquisition analysis from a discovery cohort to select precursors, peptides, and proteins that adhere to analytical criteria required for established targeted assays. TEAQ was applied to DIA‐MS data from plasma samples acquired on a new high resolution accurate mass (HRAM) mass spectrometry platform where precursors were evaluated for linearity, specificity, repeatability, reproducibility, and intra‐protein correlation based on 8‐ or 11‐point loading curves at three throughputs. This data can be used as a general resource for developing other targeted assays. TEAQ analysis of data from a case and control cohort for inflammatory bowel disease ( n =492) identified 1110 signature peptides for 326 quantifiable proteins from the 1179 identified proteins. Applying TEAQ analysis to discovery data will streamline targeted assay development and the transition to validation and clinical studies.


  • Apolipoproteins Quantified Using Blood Volumetric Absorptive Microsampling and High-Throughput Mass Spectrometry for Risk Assessment in Ischemic Heart Disease

    by Paul Marano, Kelly Mouapi, Andy Kim, Mitra Mastali, Irene van Den Broek, Danica Manalo, Qin Fu, Susan Cheng, Chrisandra Shufelt, Brennan Spiegel, et al.

  • Open Access

    Assessment of a 60-Biomarker Health Surveillance Panel (HSP) on Whole Blood from Remote Sampling Devices by Targeted LC/MRM-MS and Discovery DIA-MS Analysis

    by Stephen A. Whelan, Nathan Hendricks, Zachary L. Dwight, Qin Fu, Annie Moradian, Jennifer E. Van Eyk, Susan M. Mockus

    Telehealth, accessing healthcare and wellness remotely, should be a cost-effective and efficient way for individuals to receive care. The convenience of having a reliable remote collection device for blood tests will facilitate access to precision medicine and healthcare. Herein, we tested a 60-biomarker health surveillance panel (HSP), containing 35 FDA/LDT assays and covering at least 14 pathological states, on 8 healthy individuals' ability to collect their own capillary blood from a lancet finger prick and directly compared it to the traditional phlebotomist venous blood and plasma collection methods. All samples were spiked with 114 stable-isotope-labeled (SIL) HSP peptides and quantitatively analyzed by liquid chromatography-multiple reaction monitoring-mass spectrometry (LC/MRM-MS) scheduled method targeting 466 transitions from 114 HSP peptides and by a discovery data-independent acquisition mass spectrometry (DIA-MS) method. The average peak area ratio (PAR) of the HSP quantifier peptide transitions from all 8 volunteers' capillary blood (n = 48), venous blood (n = 48), and matched plasma (n = 24) was 90% similarity. Discovery DIA-MS analysis of the same samples using a plasma spectral library and a pan-human spectral library identified 1121 and 4661 total proteins, respectively. In addition, at least 122 FDA-approved biomarkers were identified. DIA-MS analysis reproducibly quantitated (<30% CV) ∼600-700 proteins in capillary blood, ∼800 proteins in venous blood, and ∼300-400 proteins in plasma, demonstrating that an expansive biomarker panel is possible with current mass spectrometry technology. Both targeted LC/MRM-MS and discovery DIA-MS analysis of whole blood collected on remote sampling devices are viable options for personal proteome biosignature stratification in precision medicine and precision health.


  • Application analysis and research of intelligent technology in new energy battery pack test line

    by Xiaoyan Li, Huarong Wang, Qin Fu, Hanhong Tan, Libo Yang

    Battery production is a long and complex production chain. The cell production section has been developed for more than ten years. Basically, the maturity of process and equipment standardization is relatively high, which is suitable for discrete process production. The latter power battery assembly section is an industry that has only developed in recent years. It is mostly in the exploratory stage, which is more suitable for assembly line process production. This paper explores the intellectualization of the battery pack test line. Due to the differences in the structure and assembly of the battery pack, it is the future development trend to configure intelligent equipment such as robot, conveyor line, visual positioning, special equipment, and special detection instruments to complete the battery pack test. This paper will explore the application of intelligent technology in the battery pack test and verification, Explore the intellectualization and automation of assembly and testing production line. Solve the big problem of large number of personnel and low work efficiency for enterprises and provide high-quality test data.

  • Automated proteomic sample preparation: The key component for high throughput and quantitative mass spectrometry analysis

    by Qin Fu, Christopher I. Murray, Oleg A. Karpov, Jennifer E. Van Eyk

    Sample preparation for mass spectrometry‐based proteomics has many tedious and time‐consuming steps that can introduce analytical errors. In particular, the steps around the proteolytic digestion of protein samples are prone to inconsistency. One route for reliable sample processing is the development and optimization of a workflow utilizing an automated liquid handling workstation. Diligent assessment of the sample type, protocol design, reagents, and incubation conditions can significantly improve the speed and consistency of preparation. When combining robust liquid chromatography‐mass spectrometry with either discovery or targeted methods, automated sample preparation facilitates increased throughput and reproducible quantitation of biomarker candidates. These improvements in analysis are also essential to process the large patient cohorts necessary to validate a candidate biomarker for potential clinical use. This article reviews the steps in the workflow, optimization strategies, and known applications in clinical, pharmaceutical, and research fields that demonstrate the broad utility for improved automation of sample preparation in the proteomic field.


  • Identification of Putative Early Atherosclerosis Biomarkers by Unsupervised Deconvolution of Heterogeneous Vascular Proteomes

    by Sarah J. Parker, Lulu Chen, Weston Spivia, Georgia Saylor, Chunhong Mao, Vidya Venkatraman, Ronald J. Holewinski, Mitra Mastali, Rakhi Pandey, Grace Athas, et al.

    Coronary artery disease remains a leading cause of death in industrialized nations, and early detection of disease is a critical intervention target to effectively treat patients and manage risk. Proteomic analysis of mixed tissue homogenates may obscure subtle protein changes that occur uniquely in underlying tissue subtypes. The unsupervised ‘convex analysis of mixtures’ (CAM) tool has previously been shown to effectively segregate cellular subtypes from mixed expression data. In this study, we hypothesized that CAM would identify proteomic information specifically informative to early atherosclerosis lesion involvement that could lead to potential markers of early disease detection. We quantified the proteome of 99 paired abdominal aorta (AA) and left anterior descending coronary artery (LAD) specimens (N = 198 specimens total) acquired during autopsy of young adults free of diagnosed cardiac disease. The CAM tool was then used to segregate protein subsets uniquely associated with different underlying tissue types, yielding markers of normal and fibrous plaque (FP) tissues in LAD and AA (N = 62 lesions markers). CAM-derived FP marker expression was validated against pathologist estimated luminal surface involvement of FP, as well as in an orthogonal cohort of “pure” fibrous plaque, fatty streak, and normal vascular specimens. A targeted mass spectrometry (MS) assay quantified 39 of 62 CAM-FP markers in plasma from women with angiographically verified coronary artery disease (CAD, N = 46) or free from apparent CAD (control, N = 40). Elastic net variable selection with logistic regression reduced this list to 10 proteins capable of classifying CAD status in this cohort with <6% misclassification error, and a mean area under the receiver operating characteristic curve of 0.992 (confidence interval 0.968–0.998) after cross validation. The proteomics-CAM workflow identified lesion-specific molecular biomarker candidates by distilling the most representative molecules from heterogeneous tissue types.